Cyclopharm (ASX:CYC) entered an agreement with Hospital Corporation of America Healthcare (HCA) to deploy its Technegas technology to the healthcare services provider's nuclear medicine departments, according to a Thursday filing with the Australian bourse.
The deal, initiated by HCA after multiple of its sites expressed interest, streamlines the process by bypassing individual contract negotiations, the filing said.
Technegas is used to diagnose lung conditions like pulmonary embolism, chronic obstructive pulmonary disease, and hypertension, the filing added.
The agreement also opens doors to collaboration with HealthTrust Purchasing Group, HCA's group purchasing organization, the company said.
Cyclopharm will now engage directly with individual HCA locations to roll out the technology, the company added.
The company's shares surged almost 13% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.